1. Recent National and Regional Drug Reforms in Sweden

   • Björn Wettermark
   • Brian Godman
   • Vittorio Bertelé

   Current Opinion 22 September 2012 Pages: 537 - 550

   

2. Pharmaceutical Risk-Sharing Agreements

   • Joseph P. Cook
   • John A. Vernon
   • Richard Manning

   Current Opinion 22 September 2012 Pages: 551 - 556

   

3. Does Direct-to-Consumer Advertising of Antidepressants Lead to a Net Social Benefit?

   • Jon Jureidini
   • Barbara Mintzes
   • Melissa Raven

   Commentary 22 September 2012 Pages: 557 - 566

   

4. The Author’s Reply

   • Adam E. Block

   The Author’s Reply 22 September 2012 Pages: 567 - 568

5. Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes

   • Stefan Vegter
   • Cornelis Boersma
   • Maarten J. Postma

   Review Article 22 September 2012 Pages: 569 - 587

   

6. Future Drug Prices and Cost-Effectiveness Analyses

   • Martin Hoyle

   Original Research Article 22 September 2012 Pages: 589 - 602

   

7. Generic Entry, Reformulations and Promotion of SSRIs in the US

   • Haiden A. Huskamp
   • Julie M. Donohue
   • Richard G. Frank

   Original Research Article 22 September 2012 Pages: 603 - 616

   

8. Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

   • Ray Gani
   • Gavin Giovannoni
   • John Kerrigan

   Original Research Article 22 September 2012 Pages: 617 - 627